Managers / Q4 2024 · view latest →
Foresite Capital Management VI LLC
CIK 0002013341 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887
Summary
Foresite Capital Management Vi LLC reported $224M in U.S.-listed holdings across 14 positions for Q4 2024.
The portfolio is heavily concentrated: CGON alone accounts for 28.4% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 75.1% · $169M
- ADR · 14.4% · $32M
- Other · 10.5% · $24M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | NEW | +2.22M | 2.22M | +$64M | $64M |
| ALMSAlumis Inc | NEW | +4.20M | 4.20M | +$33M | $33M |
| 260Centessa Pharmaceuticals Inc | NEW | +1.25M | 1.25M | +$21M | $21M |
| Rapt Therapeutics Inc | NEW | +12.50M | 12.50M | +$20M | $20M |
| BCAXBicara Therapeutics Inc | NEW | +950.0K | 950.0K | +$17M | $17M |
| EWTXEdgewise Therapeutics Inc | NEW | +585.0K | 585.0K | +$16M | $16M |
| GPCRStructure Therapeutics Inc | NEW | +420.0K | 420.0K | +$11M | $11M |
| AKROAkero Therapeutics Inc | NEW | +365.0K | 365.0K | +$10M | $10M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc.history → | COM | 28.39% | $64M | 2.22M |
| 2 | ALMSAlumis Inchistory → | COM | 14.72% | $33M | 4.20M |
| 3 | 260Centessa Pharmaceuticals Inchistory → | SPONSORED ADS | 9.35% | $21M | 1.25M |
| 4 | Rapt Therapeutics Inc | COM | 8.80% | $20M | 12.50M |
| 5 | BCAXBicara Therapeutics Inchistory → | COM | 7.37% | $17M | 950.0K |
| 6 | EWTXEdgewise Therapeutics Inchistory → | COM | 6.96% | $16M | 585.0K |
| 7 | GPCRStructure Therapeutics Inchistory → | SPONSORED ADS | 5.08% | $11M | 420.0K |
| 8 | AKROAkero Therapeutics Inchistory → | COM | 4.52% | $10M | 365.0K |
| 9 | CRVSCorvus Pharmaceuticals Inchistory → | COM | 3.77% | $8M | 1.58M |
| 10 | CGEMCullinan Therapeutics Inchistory → | COM | 3.44% | $8M | 634.6K |
| 11 | ALLOAllogene Therapeutics Inchistory → | COM | 3.27% | $7M | 3.45M |
| 12 | KYMRKymera Therapeutics Inchistory → | COM | 2.62% | $6M | 146.3K |
| 13 | Casi Pharmaceuticals Inc | ORD SHS | 1.68% | $4M | 1.33M |
| 14 | VRDNViridian Therapeutics, Inc | COM | 0.02% | $37,842 | 2.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $460M | 17 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $331M | 12 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $259M | 12 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $178M | 20 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $183M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $224M | 14 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.